恩度联合化疗药物治疗恶性胸腹腔积液的临床观察

目的 观察胸膜腔及腹腔内注入重组人血管内皮抑素(恩度)联合化疗药物治疗癌性胸腹水的疗效及安全性.方法 46例晚期癌性胸、腹水患者,其中实验组23例分别在胸膜腔或腹腔内注入恩度30mg-60mg和化疗药物(胸水者予以DDP 60mg+IL-2 200万U或BLM 60mg+IL-2 200万U;腹水者予以DDP 60mg+5-FU 1.0+ IL-2 200万U)治疗,对照组23例仅在胸膜腔或腹腔内注入化疗药物(胸水者予以DDP 60mg+IL-2 200万U或BLM 60mg+IL-2 200万U;腹水者予以DDP 60mg+5-FU 1.0+ IL-2 200万U)治疗,每7天一次连续给药2-4次,参照RECISE非靶病灶评价方法和WHO毒性反应分级标准,评价客观疗效及不良反应,并由KPS评分变化情况评价患者的生活质量改善.结果 实验组23例患者CR 8 例、PR 9例、NC 6例,有效率73.1%,对照组23例患者CR 6 例、PR 7例、NC 10例,有效率55.6%,两组差异有统计学意义P<0.05;实验组患者QOL改善稳定率为82.6%;对照组患者QOL改善率73.9%;两组差异有统计学意义P<0.05.结论 胸膜腔、腹腔内注入恩度和化疗药物治疗癌性胸腹水有较高的疗效且不良反应少.

clinical observation of Endostatin combined with chemotherapy in treating malignant hydrothorax

Objective:To observe the efficacy and safety of recombinant human endostatin(ex)combined with chemotherapy in the treatment of malignant pleural effusion and ascites.Methods: Total of 46 cases with malignant pleural and ascitic were involved in the study.For research group 23 cases,were treated with recombinant human endostatin(ex)combined with chemotherapy.For control group 23 cases,were treated with chemotherapy.Once every 7 days administration 2-4 times in a row for all patients.According to RECIST criteria and WHO toxicity classification standard,the efficacy and toxicity were evaluated respectively.from KPS score was observed to evaluate the changes of patients’ quality of life.Results:Among research group 23 cases,there were CR 8 cases,PR 9 cases,NC 6 cases,overall response rate was 73.1%,controlled group 23 cases CR 6 cases,PR 7 cases,NC 10 cases,overall response rate was 55.6%,(P=0.021);experimental group patients QOL improve stability rate 82.6%;controlled group patients QOL improve rate 73.9%(P=0.039).Conclusion: Recombinant human endostatin(ex)combined with chemotherapy in the treatment of malignant pleural effusion and ascites is an effective and safe regimen.